Promising target improves antitumor response in preclinical models of pancreatic cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 18-Dec-2025 23:11 ET (19-Dec-2025 04:11 GMT/UTC)
TAMEST (Texas Academy of Medicine, Engineering, Science and Technology) has announced Maralice Conacci-Sorrell, Ph.D., Associate Professor, Department of Cell Biology at UT Southwestern Medical Center, as the recipient of the 2026 Mary Beth Maddox Award and Lectureship in cancer research. She was chosen for her pioneering research revealing how cancer cells harness nutrients to drive their growth and for creating targeted strategies to suppress otherwise untreatable cancers.
Kyoto, Japan -- Colorectal cancer, or CRC, is the world's second most lethal cancer based on the number of deaths, and is the third most prevalent malignant tumor. Doctors and patients have long been hoping for better diagnostics for prognosis, such as molecular subtyping, which uses data collected from cancer stem cells, or tumor-initiating cells, to further divide one type of cancer into subgroups. It may correlate with patient outcomes and enable better prognoses.
Though many CRC tissue samples have been analyzed and classified based on mRNA gene expression, currently the practical application of these studies in patient prognosis is limited for colorectal cancer. This motivated a team of researchers from Kyoto University to examine cancer stem cells for the molecular subtyping of CRC.
"We need more comprehensive and clinically useful markers and their signatures to help predict the outcome of each patient," says first author Fumihiko Kakizaki.
EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a full-blown immunotherapy strategy.